جست‌وجوی استاد و پژوهشگر

Tim Clausenمشاهده پروفایل

استاد

• Protein Quality Control
• Post-translational Modifications
• Bacterial Stress Response
• +۴ مورد دیگر

Tim Clausen serves as Senior Group Leader at the Research Institute of Molecular Pathology (IMP) in Vienna, leading his research group continuously since 2002 (promoted to Senior Group Leader in 2009). Previously, he established his independent research program as Group Leader at the Max-Planck-Institute of Biochemistry (1999-2002). His educational background includes: PhD from Technical University Munich (1997) Postdoctoral research at Max-Planck-Institute of Biochemistry Dr. Clausen's research centers on molecular mechanisms of protein quality control , with three interconnected pillars: Bacterial stress response : Discovery of phospho-arginine (pArg) as a degradation tag analogous to ubiquitin, mediated by McsB kinase and ClpCP protease Muscle protein assembly : UNC-45 chaperone's dual role in myosin folding and stress-induced degradation Targeted protein degradation : Structural and mechanistic studies of giant E3/E4 ubiquitin ligases (UBR4, Huwe1) These investigations reveal fundamental principles of cellular protein homeostasis with implications for infectious disease and myopathies. Analysis of recent publications (2016-2025) shows consistent focus on structural mechanisms of degradation pathways, evolving from bacterial pArg signaling to eukaryotic ubiquitin systems. Key breakthroughs include establishing the pArg-ClpCP pathway as a simplified bacterial analog of ubiquitin-proteasome systems and developing BacPROTACs for targeted bacterial protein degradation. Current funding includes: ERC Advanced Grant MUSCLE-QC FWF grants: ELLIPSE, PROTAC, bacPROTAC2, MYOSYN Paul G Allen Foundation PRO-Watch Dr. Clausen actively mentors students through the Vienna BioCenter PhD Program (application deadlines March 1/September 1) and welcomes direct inquiries from master students/postdocs. The lab operates within IMP's collaborative environment featuring state-of-the-art core facilities and strong industry partnerships. Research directions increasingly emphasize translational applications of protein degradation mechanisms for therapeutic development.

• Medical Oncology
• Genitourinary Oncology
• Prostate Cancer
• +۷ مورد دیگر

Daniel P. Petrylak is Professor of Medicine (Medical Oncology) and Urology at Yale School of Medicine and serves as Chief of Genitourinary Oncology at Yale Cancer Center. He joined the Yale faculty in 2012 after completing his medical training, which included an MD from Case Western Reserve University School of Medicine (1985), residency and internship at Bronx Municipal Hospital, and fellowship at Memorial Sloan-Kettering Cancer Center. Dr. Petrylak is a pioneer in developing new drugs and treatments for prostate, bladder, kidney, and testicular cancers. His research focuses on translating basic science discoveries into clinical applications, with particular interest in immunotherapy advancements for genitourinary cancers. As co-director of the Signal Transduction Research Program at Yale Cancer Center, he works with approximately 40 physicians and scientists to understand how cancer stem cells are regulated and communicate with surrounding tissue. His recent publications (2024-2025) demonstrate a strong focus on novel therapeutic approaches for advanced urothelial and prostate cancers, including antibody-drug conjugates (sacituzumab govitecan, enfortumab vedotin), immunotherapy combinations, and targeted therapies. His work spans clinical trial design, biomarker analysis, and patient-reported outcomes, reflecting a comprehensive approach to improving cancer treatment. Dr. Petrylak currently serves as principal investigator or co-principal investigator on seven Southwest Oncology Group clinical trials for genitourinary cancers. He has authored more than 100 peer-reviewed articles on prostate and bladder cancer research, with recent work appearing in high-impact journals including Journal of Clinical Oncology, Cancer Discovery, and JAMA Network Open. At Smilow Cancer Hospital, Dr. Petrylak leverages his national leadership in clinical trials to provide New England patients with access to the latest investigational drugs while maintaining the highest standards of care. His philosophy emphasizes translating research breakthroughs into tangible patient benefits, as evidenced by his role in moving docetaxel therapy for advanced prostate cancer from phase I to III trials, which supported its regulatory approval.

Marie Lopezمشاهده پروفایل

پژوهشگر

• Chemobiology
• Epigenetics
• Enzyme inhibitors
• +۶ مورد دیگر

Dr. Marie Lopez is a Research Officer at the National Center for Scientific Research (CNRS) leading the 'A1 - Glycochemistry & Molecular Recognition' group at IBMM, Montpellier. Her career includes positions at Griffith Institute for Drug Discovery (Brisbane), IRIM/IBMM (Montpellier), and ETaC laboratory (Toulouse). She holds a PhD in Chemistry from the University of Grenoble. Her research integrates: Chemobiology : Developing chemical probes and enzyme inhibitors Epigenetics : Targeting DNA methylation and epigenetic modifications Therapeutic innovation : Applying PROTAC technology and anti-infective strategies with focus areas spanning glycochemistry, tuberculosis research, and disease mechanisms.

Yonathan Lissanuمشاهده پروفایل

دانشیار

• Epigenetics
• Chromatin Remodeling
• Lung Cancer
• +۵ مورد دیگر

Yonathan Lissanu, MD, PhD is an Associate Professor in the Department of Thoracic and Cardiovascular Surgery - Research within the Division of Surgery at The University of Texas MD Anderson Cancer Center, with a joint appointment in the Department of Genomic Medicine. His research program focuses on understanding the molecular basis of cancers with genomic alterations in chromatin and epigenetic regulators, with particular emphasis on lung cancer. Dr. Lissanu's research interests center on identifying therapeutically relevant vulnerabilities in tumors with mutations in chromatin remodeling complexes, particularly the SWI/SNF complex. His laboratory employs functional genomics, mouse genetics, and chemical biology approaches to elucidate genetic vulnerabilities in cancer subtypes. A major focus of his work involves targeted protein degradation using proteolysis targeting chimeras (PROTACs) against cancer-relevant targets like glucocorticoid receptor (GR) and SMARCA2. His team has made significant contributions to understanding how SWI/SNF mutations create metabolic dependencies on oxidative phosphorylation and confer resistance to immunotherapies. Analysis of Dr. Lissanu's publication record reveals a strong focus on chromatin biology and cancer therapeutics, with particular emphasis on SWI/SNF complex mutations across multiple cancer types. His work bridges basic science discoveries with therapeutic development, particularly in the areas of targeted protein degradation and metabolic vulnerabilities. The progression of his research shows increasing sophistication in connecting molecular mechanisms to therapeutic opportunities, with recent work exploring combination strategies and resistance mechanisms. Dr. Lissanu currently mentors a research scientist, four postdoctoral fellows, an undergraduate student, and a research associate, indicating an active and growing research program. His laboratory, the Lissanu Laboratory, is dedicated to translating basic cancer biology understanding into novel cancer therapeutics, with particular focus on lung cancers with mutations in epigenetic and chromatin regulators. The laboratory actively seeks motivated graduate students and postdoctoral fellows to join their work in cancer functional genomics and therapeutics discovery.